Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA.
Clin Pharmacokinet. 2012 Jan 1;51(1):55-68. doi: 10.2165/11595650-000000000-00000.
In many clinical situations, measurement of the total drug concentration does not provide the needed information concerning the fraction of unbound drug in plasma, which is available for pharmacodynamic action. To address this, a 'normalized concentration' can be calculated on the basis of the observed total drug concentration and the serum protein level. Up to now, this method has only been applied to phenytoin. Several equations for calculating normalized concentrations of phenytoin have been published, many leading to different results. Regrettably, all of the equations in the current literature are based on an outdated model of drug binding to human serum albumin and are based on the fraction of unbound drug, which is known to depend on both protein and drug concentrations. In response to the relatively new scientific evidence about drug binding to human plasma proteins, the objective of the present study is to develop a general method for calculating normalized drug concentrations in the presence of altered plasma protein binding.
When several drug molecules can be bound by a protein molecule, multiple equilibria are established; these equilibria may be formulated in terms of a stoichiometric analysis or a site-oriented analysis. Both models are currently encountered in the scientific literature, sometimes without clear identification of which model is used. The present study presents the basic equations for both models and shows how the normalized concentration can be calculated on the basis of the measured drug concentration, the protein level and the binding constants.
The normalized concentration can be calculated for any drug, using the same simple equation regardless of the binding model and the number of binding proteins. Explicit solutions are presented for particular cases of clinical importance. The new model is validated by comparison with the Winter-Tozer equation for calculating the normalized phenytoin concentration and is found to be equivalent for concentrations close to therapeutic concentrations. In the case of phenytoin, the main advantage of the new equation is that it also works outside the linear binding range.
A new comprehensive method for calculating normalized drug concentrations is developed, allowing drug concentrations to be interpreted correctly in cases of altered drug-protein binding. The calculations are based on binding constants and are applicable to any protein level and drug concentration, without being limited to linear binding of drugs to proteins. The new model is expected to become important in pharmacokinetic-pharmacodynamic modelling, allometric scaling and population pharmacokinetics because it provides the ability to accurately take into account physiological and pathological changes in protein binding. As a direct clinical application, the equations can be used to calculate normalized drug concentrations in patients with abnormal protein levels, such as the elderly, trauma patients and paediatric patients.
在许多临床情况下,测量总药物浓度并不能提供有关血浆中未结合药物部分的信息,而这部分药物可用于药效作用。为了解决这个问题,可以根据观察到的总药物浓度和血清蛋白水平计算“归一化浓度”。到目前为止,这种方法仅应用于苯妥英。已经发表了许多计算苯妥英归一化浓度的公式,但许多公式的结果不同。遗憾的是,目前文献中的所有公式都基于过时的人血清白蛋白药物结合模型,并且基于已知依赖于蛋白质和药物浓度的未结合药物部分。针对关于药物与人血浆蛋白结合的相对较新的科学证据,本研究的目的是开发一种在改变的血浆蛋白结合存在下计算归一化药物浓度的通用方法。
当一个蛋白质分子可以结合多个药物分子时,会建立多个平衡;这些平衡可以根据化学计量分析或基于位点的分析来表述。目前在科学文献中都遇到这两种模型,有时没有明确识别使用的是哪种模型。本研究介绍了这两种模型的基本方程,并展示了如何根据测量的药物浓度、蛋白水平和结合常数计算归一化浓度。
可以使用相同的简单方程计算任何药物的归一化浓度,而与结合模型和结合蛋白的数量无关。给出了临床重要特定情况的显式解。通过与计算归一化苯妥英浓度的 Winter-Tozer 方程进行比较验证了新模型的有效性,并且发现它在接近治疗浓度的情况下等效。对于苯妥英,新方程的主要优点是它也适用于线性结合范围之外。
开发了一种计算归一化药物浓度的新综合方法,可以在药物-蛋白结合改变的情况下正确解释药物浓度。计算基于结合常数,适用于任何蛋白水平和药物浓度,不受药物与蛋白线性结合的限制。新模型有望在药代动力学-药效学模型、比例缩放和群体药代动力学中变得重要,因为它提供了准确考虑蛋白结合生理和病理变化的能力。作为直接的临床应用,该方程可用于计算异常蛋白水平患者(如老年人、创伤患者和儿科患者)的归一化药物浓度。